Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer's Disease Treatment

ADAM (a disintegrin and metalloproteinase) is a family of widely expressed, transmembrane and secreted proteins of approximately 750 amino acids in length with functions in cell adhesion and proteolytic processing of the ectodomains of diverse cell-surface receptors and signaling molecules. ADAM10 i...

Full description

Bibliographic Details
Authors: Peron, Rafaela; Pereira Vatanabe, Izabela; Manzine, Patricia; Camins Espuny, Antoni; Cominetti, Márcia Regina
Format: Article
Status:Published version
Publication date:2018
Country:España
Institution:Universidad de Barcelona
Repository:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/174444
Online Access:https://hdl.handle.net/2445/174444
Access Level:Open access
Keyword:Malaltia d'Alzheimer
Proteïnes
Farmacologia
Alzheimer's disease
Proteins
Pharmacology
_version_ 1878741770168172544
author Peron, Rafaela
author2 Pereira Vatanabe, Izabela
Manzine, Patricia
Camins Espuny, Antoni
Cominetti, Márcia Regina
author2_role author
author
author
author
author_browse Camins Espuny, Antoni
Cominetti, Márcia Regina
Manzine, Patricia
Pereira Vatanabe, Izabela
Peron, Rafaela
author_facet Peron, Rafaela
Pereira Vatanabe, Izabela
Manzine, Patricia
Camins Espuny, Antoni
Cominetti, Márcia Regina
author_role author
collection Dipòsit Digital de la UB
description ADAM (a disintegrin and metalloproteinase) is a family of widely expressed, transmembrane and secreted proteins of approximately 750 amino acids in length with functions in cell adhesion and proteolytic processing of the ectodomains of diverse cell-surface receptors and signaling molecules. ADAM10 is the main α-secretase that cleaves APP (amyloid precursor protein) in the non-amyloidogenic pathway inhibiting the formation of β-amyloid peptide, whose accumulation and aggregation leads to neuronal degeneration in Alzheimer's disease (AD). ADAM10 is a membrane-anchored metalloprotease that sheds, besides APP, the ectodomain of a large variety of cell-surface proteins including cytokines, adhesion molecules and notch. APP cleavage by ADAM10 results in the production of an APP-derived fragment, sAPPα, which is neuroprotective. As increased ADAM10 activity protects the brain from β-amyloid deposition in AD, this strategy has been proved to be effective in treating neurodegenerative diseases, including AD. Here, we describe the physiological mechanisms regulating ADAM10 expression at different levels, aiming to propose strategies for AD treatment. We report in this review on the physiological regulation of ADAM10 at the transcriptional level, by epigenetic factors, miRNAs and/or translational and post-translational levels. In addition, we describe the conditions that can change ADAM10 expression in vitro and in vivo, and discuss how this knowledge may help in AD treatment. Regulation of ADAM10 is achieved by multiple mechanisms that include transcriptional, translational and post-translational strategies, which we will summarize in this review.
eu_rights_str_mv openAccess
format article
id ES_eb155b7b1fb2c8dafdcb2ae56caa5fe6
institution Universidad de Barcelona
instname_str Universidad de Barcelona
network_acronym_str ES
network_name_str España
oai_identifier_str oai:diposit.ub.edu:2445/174444
publishDate 2018
publishDateSort 2018
publisher MDPI
publisherStr MDPI
reponame_str Dipòsit Digital de la UB
spelling Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer's Disease Treatment Peron, Rafaela Pereira Vatanabe, Izabela Manzine, Patricia Camins Espuny, Antoni Cominetti, Márcia Regina Malaltia d'Alzheimer Proteïnes Farmacologia Alzheimer's disease Proteins Pharmacology ADAM (a disintegrin and metalloproteinase) is a family of widely expressed, transmembrane and secreted proteins of approximately 750 amino acids in length with functions in cell adhesion and proteolytic processing of the ectodomains of diverse cell-surface receptors and signaling molecules. ADAM10 is the main α-secretase that cleaves APP (amyloid precursor protein) in the non-amyloidogenic pathway inhibiting the formation of β-amyloid peptide, whose accumulation and aggregation leads to neuronal degeneration in Alzheimer's disease (AD). ADAM10 is a membrane-anchored metalloprotease that sheds, besides APP, the ectodomain of a large variety of cell-surface proteins including cytokines, adhesion molecules and notch. APP cleavage by ADAM10 results in the production of an APP-derived fragment, sAPPα, which is neuroprotective. As increased ADAM10 activity protects the brain from β-amyloid deposition in AD, this strategy has been proved to be effective in treating neurodegenerative diseases, including AD. Here, we describe the physiological mechanisms regulating ADAM10 expression at different levels, aiming to propose strategies for AD treatment. We report in this review on the physiological regulation of ADAM10 at the transcriptional level, by epigenetic factors, miRNAs and/or translational and post-translational levels. In addition, we describe the conditions that can change ADAM10 expression in vitro and in vivo, and discuss how this knowledge may help in AD treatment. Regulation of ADAM10 is achieved by multiple mechanisms that include transcriptional, translational and post-translational strategies, which we will summarize in this review. MDPI https://hdl.handle.net/2445/174444
spellingShingle Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer's Disease Treatment
Peron, Rafaela
Malaltia d'Alzheimer
Proteïnes
Farmacologia
Alzheimer's disease
Proteins
Pharmacology
status_str publishedVersion
title Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer's Disease Treatment
title_full Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer's Disease Treatment
title_fullStr Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer's Disease Treatment
title_full_unstemmed Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer's Disease Treatment
title_short Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer's Disease Treatment
title_sort Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer's Disease Treatment
topic Malaltia d'Alzheimer
Proteïnes
Farmacologia
Alzheimer's disease
Proteins
Pharmacology
topic_facet Malaltia d'Alzheimer
Proteïnes
Farmacologia
Alzheimer's disease
Proteins
Pharmacology
url https://hdl.handle.net/2445/174444